Galea Life Sciences, Inc. Announces Completion of 2008 Audit
08 Giugno 2009 - 4:35PM
Marketwired
Galea Life Sciences, Inc., maker of Nutraplete(TM) therapeutic
drink mix and a pioneer in the field of therapeutic nutrition,
announces the completion of its financial audit for its fiscal year
ended October 31, 2008. The Company intends to file a new Form 10
registration statement with the SEC. The Company expects its Common
stock to open trading on the Over The Counter Bulletin Board
(OTCBB), if and when it clears SEC comments on the Form 10, and
FINRA has accepted the Company's stock for quotation.
About Nutraplete(TM)
Nutraplete Therapeutic Drink Mix is the first therapeutic
nutritional dietary supplement created specifically to help people
living with HIV/AIDS. This multi-nutritional, therapeutic
"functional food" includes pharmaceutical grade supplements that
may provide health benefits by addressing common nutritional
deficiencies. Nutraplete is available by prescription and currently
approved for Medicaid reimbursement in New York State, New Jersey,
Connecticut, Illinois, Nevada and Washington State. The company is
currently seeking Medicaid approval in California, Florida,
Pennsylvania, Maryland, Washington, D.C. and other states. For more
information: www.nutraplete.com
Nutraplete is distributed exclusively in the U.S. by Allion
Healthcare, Inc. (www.allionhealthcare.com) (NASDAQ: ALLI) under
its MOMS Pharmacy trade name. MOMS Pharmacy is a specialty pharmacy
that is focused exclusively on providing medications and support
services to people living with HIV/AIDS. Visit
www.momspharmacy.com.
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. focuses on the emerging field of
advanced nutritional supplements designed to support traditional
medical treatments and therapies, and specializes in the
formulation, manufacturing, marketing and distribution of
innovative dietary supplements that benefit people undergoing
medical treatments and therapies. Nutraplete is its introductory
product.
Certain statements in this release constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words "forecast,"
"project," "intend," "expect," "should," "would," and similar
expressions and all statements, which are not historical facts, are
intended to identify forward-looking statements. These
forward-looking statements involve and are subject to known and
unknown risks, uncertainties and other factors which could cause
the Company's actual results, performance (finance or operating) or
achievements to differ from future results, performance (financing
and operating) or achievements expressed or implied by such
forward-looking statements.
Statements herein express management's beliefs and expectations
regarding future performance and are forward-looking and involve
risks and uncertainties, including, but not limited to, the ability
to negotiate outstanding prior debts of acquired companies;
properly identify acquisition partners; adequately perform due
diligence; manage and integrate acquired businesses; react to
quarterly fluctuations in results; raise working capital and secure
other financing; respond to competition and rapidly changing
technology; deal with market and stock price fluctuations; and
other risks.
For more information: Paul Zuromski President Galea Life
Sciences, Inc 877-576-8872
Grafico Azioni Allion Healthcare (MM) (NASDAQ:ALLI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Allion Healthcare (MM) (NASDAQ:ALLI)
Storico
Da Set 2023 a Set 2024